Inhibikase Therapeutics Inc (IKT) Stock Price, Quote & News

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia....

Industry: Biotechnology

Sector: Healthcare

Phone: (678) 392-3419

Website: www.inhibikase.com

Address:

3350 Riverwood Parkway SE, Suite 1900, Atlanta, United States

Finanz Jul. 5 at 8:03 PM

$IKT Time for a short squeeze?

0 · Reply

TJC1791 Jun. 30 at 10:20 PM

$IKT https://www.ainvest.com/news/inhibikase-therapeutics-russell-2500-inclusion-strategic-pivot-small-cap-biotech-investors-parkinson-pipeline-shifts-2507/

1 · Reply

TJC1791 Jun. 28 at 4:31 PM

$IKT @PharmToBank how you feeling about this recent imatinib trial that seems to be well tolerated? Any concerns on the viability of IKT pro?

1 · Reply

Mjf04288 Jun. 28 at 2:05 AM

$IKT What is going on? After hours volume 7.06 million

1 · Reply

stockanalysis_ Jun. 27 at 9:48 PM

After Hours Losers: $SERA $ODYS $AMIX $INTG $IKT View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading

0 · Reply

WillisMcGillis Jun. 26 at 8:06 PM

$IKT Phase 3 Risvo https://www.globenewswire.com/news-release/2025/05/21/3085719/0/en/ABLi-Therapeutics-Announces-Details-of-the-End-of-Phase-2-Meeting-with-FDA-for-Evaluation-of-Risvodetinib-as-a-Treatment-for-Parkinson-s-Disease.html

2 · Reply

Major_Bagholder Jun. 21 at 6:08 PM

$IKT How does the share price not immediately drop below a $1 with this filing?

2 · Reply

DonCorleone77 Jun. 21 at 1:42 PM

$IKT Inhibikase Therapeutics files $300M mixed securities shelf

1 · Reply

Mjf04288 Jun. 20 at 10:17 PM

$IKT S-3 filed after close

0 · Reply

BiotechJedi1728 Jun. 18 at 11:55 AM

$IKT Why did that feel like an attempt at a flush out yesterday before an announcement is made? I just hate the greedy fvcks here… Just make your money. Stop messing with the SP. 🤦🏻‍♂️ You know what. F. That. I am buying this morning.

1 · Reply

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

Apr 14, 2025, 8:00 AM EDT - 3 months ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Mar 27, 2025, 4:01 PM EDT - 3 months ago

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Feb 24, 2025, 8:00 AM EST - 4 months ago

Inhibikase Announces Expansion of Senior Leadership Team

Feb 18, 2025, 8:00 AM EST - 5 months ago

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Jan 29, 2025, 6:30 PM EST - 5 months ago

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Nov 19, 2024, 1:32 PM EST - 8 months ago

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Nov 14, 2024, 8:37 AM EST - 8 months ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Oct 21, 2024, 9:05 AM EDT - 9 months ago

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 9, 2024, 9:18 AM EDT - 9 months ago

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Aug 15, 2024, 6:13 PM EDT - 11 months ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:25 PM EDT - 11 months ago

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 17, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Jun 5, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

May 20, 2024, 8:01 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

May 17, 2024, 9:57 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

May 15, 2024, 8:00 PM EDT - 1 year ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 15, 2024, 8:45 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

May 9, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Apr 3, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Mar 28, 2024, 5:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:15 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Mar 7, 2024, 8:30 AM EST - 1 year ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Feb 28, 2024, 4:05 PM EST - 1 year ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Feb 7, 2024, 7:55 AM EST - 1 year ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Jan 29, 2024, 9:05 AM EST - 1 year ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Jan 16, 2024, 4:05 PM EST - 1 year ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Dec 4, 2023, 8:35 AM EST - 1 year ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Nov 15, 2023, 5:38 PM EST - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Nov 14, 2023, 4:30 PM EST - 1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Nov 7, 2023, 9:28 AM EST - 1 year ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Aug 24, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 21, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 7, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 29, 2023, 9:29 AM EDT - 2 years ago

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Jun 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Jun 21, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

May 30, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

May 16, 2023, 9:38 AM EDT - 2 years ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript

May 16, 2023, 7:45 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

May 8, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

May 4, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

Finanz Jul. 5 at 8:03 PM

$IKT Time for a short squeeze?

0 · Reply

TJC1791 Jun. 30 at 10:20 PM

$IKT https://www.ainvest.com/news/inhibikase-therapeutics-russell-2500-inclusion-strategic-pivot-small-cap-biotech-investors-parkinson-pipeline-shifts-2507/

1 · Reply

TJC1791 Jun. 28 at 4:31 PM

$IKT @PharmToBank how you feeling about this recent imatinib trial that seems to be well tolerated? Any concerns on the viability of IKT pro?

1 · Reply

Mjf04288 Jun. 28 at 2:05 AM

$IKT What is going on? After hours volume 7.06 million

1 · Reply

stockanalysis_ Jun. 27 at 9:48 PM

After Hours Losers: $SERA $ODYS $AMIX $INTG $IKT View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading

0 · Reply

WillisMcGillis Jun. 26 at 8:06 PM

2 · Reply

Major_Bagholder Jun. 21 at 6:08 PM

$IKT How does the share price not immediately drop below a $1 with this filing?

2 · Reply

DonCorleone77 Jun. 21 at 1:42 PM

$IKT Inhibikase Therapeutics files $300M mixed securities shelf

1 · Reply

Mjf04288 Jun. 20 at 10:17 PM

$IKT S-3 filed after close

0 · Reply

BiotechJedi1728 Jun. 18 at 11:55 AM

1 · Reply

Major_Bagholder Jun. 17 at 3:21 PM

$IKT Some news would be nice.

0 · Reply

Finanz Jun. 17 at 2:27 AM

$IKT The shorts seem to be in control and not ready to cover

0 · Reply

BillyTheKid62 Jun. 14 at 7:41 PM

$IKT Owning this stock is like having a bad case of hemmroids . I know because i have both !

1 · Reply

little_jackie Jun. 13 at 10:42 PM

$LYEL You guys really need to run out @BiotechJedi1728 He pumps like mad. Ask him about $IKT

0 · Reply

little_jackie Jun. 13 at 10:41 PM

$DARE You guys haven't ran out @BiotechJedi1728 yet? This guy is so full of it. Ask him about his pumping of $IKT

0 · Reply

TJC1791 Jun. 11 at 8:23 PM

$IKT Check out this job at Inhibikase Therapeutics, Inc.: https://www.linkedin.com/jobs/view/4248093871

2 · Reply

LilyR Jun. 9 at 7:28 PM

$IKT added some shares today

0 · Reply

Mjf04288 May. 27 at 8:08 PM

$IKT Kind of a weird trading day for IKT. Higher volume but finished the day right back where we started

0 · Reply

jemer May. 27 at 2:03 PM

$IKT April 30th was Russell 2000 Reconstitution Day. According to new data, companies had to have a market cap of $119.2MM to qualify. On that day, IKT had a market cap of $177MM. How are the Russell Index Mutual Funds gonna buy the millions of shares of IKT needed with such a small float available?

1 · Reply

BillyTheKid62 May. 21 at 7:52 PM

$IKT triple down , this is a pos stock .

2 · Reply

PenkeTrading May. 21 at 9:57 AM

I found you a Bullish Engulfing Candle Pattern on the daily chart of Inhibikase Therapeutics Inc. $IKT #Inhibikase #BullishEngulfingCandle #NASDAQ

0 · Reply

BillyTheKid62 May. 20 at 3:43 PM

$IKT double down , this is a pos stock .

0 · Reply

Market Cap	140.51M
Revenue (ttm)	0.00
Net Income (ttm)	-27.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	220,900
Avg Vol	280,218
Day's Range	N/A - N/A
Shares Out	74.34M
Stochastic %K	94%
Beta	0.92
Analysts	Strong Sell
Price Target	$8.00